Events
Symposium
Vaccination with CPG 7909 and Melan-A peptide: Timely, strong and repeated augmentation of circulating peptide specific CD8+ T cells in melanoma patients
Keystone Symposium 2005
unknown
Differential lytic effector function displayed by human antigen-specific effector-memory CD28+ and CD28- T lymphocyte subsets
Swiss Society for Allergology and Immunology, Berne 2005
Switzerland
Monitoring of human T cells specific for influenza virus
WHO Symposium on Influenza vaccination. Geneva 2005
unknown
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909
Progress in Vaccination against Cancer (PIVAC) meeting, Freudenstadt Germany 2004
Germany
Tumor specific T cells induced in melanoma patients either naturally or by vaccination with peptides, IFA ± CpG oligodeoxynucleotides
Cancer Research Institute Symposium, New York 2004
U.S.A.
Activation de lymphocytes anti-tumoraux lors de la progression d'un mélanome ou après vaccination
Eurocancer meeting, Paris 2004
France
Efficient expansion of antigen specific CD8 T cells in melanoma patients immunized with peptide, IFA and CpG oligonucleotide 7909
AACR congress, Orlando 2004
unknown
Ex vivo detectable activation of Melan-A specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA
Cancer Research Institute Symposium, New York 2003
U.S.A.
Ex vivo detection of activated Melan-A specific T cells after peptide vaccination
Progress in Vaccination against Cancer (PIVAC) meeting, Nottingham, UK 2002
Great Britain
Adjuvant peptide vaccination for high risk melanoma
A pilot experience. International Conference of the Royal College of Physicians, UK 2002
Great Britain
CD8+ T cell responses in melanoma patients immunized with synthetic peptides derived from the tumor antigen Melan-A and from the Influenza matrix protein
Activating Immunity with CpG Oligos: Second International Meeting, Florida 2001
unknown
T cell responses to melanoma and viral antigens : in vitro is not in vivo
8th World Congress on Cancers of the Skin. Zuerich 2001
unknown
In vivo resting, cycling, and effector CD8+ T cells differ in expression of the activatory receptor 2B4
Swiss Society for Allergology and Immunology, Lausanne 2001
Switzerland
Peptide plus adjuvant vaccination strongly and specifically activates local CD8+ T cells in Vaccine Site Sentinel Lymph Nodes (VSSN) from melanoma patients
5th World Conference in Melanoma, Venice 2001
unknown
Human circulating HLA-DR+ CD8+ T cells proliferate and show telomerase activity in vivo and are distinct from cytolytic effector T cells
Congress European Network of Institutes in Immunology. Les Embiez 2000
unknown
In vivo expression of natural killer inhibitory receptors by human melanoma specific cytolytic T lymphocytes
Swiss Society for Allergology and Immunology, Interlaken 1999
Switzerland
